CombiGene AB (publ) reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported sales was SEK 5.35 million compared to SEK 84.04 million a year ago. Net loss was SEK 11.94 million compared to net income of SEK 57.45 million a year ago. Basic loss per share from continuing operations was SEK 0.6 compared to basic earnings per share from continuing operations of SEK 2.9 a year ago. Diluted loss per share from continuing operations was SEK 0.6 compared to diluted earnings per share from continuing operations of SEK 2.9 a year ago.
For the full year, sales was SEK 26.7 million compared to SEK 84.04 million a year ago. Net loss was SEK 6.16 million compared to net income of SEK 20.97 million a year ago. Basic loss per share from continuing operations was SEK 0.31 compared to basic earnings per share from continuing operations of SEK 1.21 a year ago. Diluted loss per share from continuing operations was SEK 0.31 compared to diluted earnings per share from continuing operations of SEK 1.21 a year ago.